Division of Nephrology, Laboratory of Nephrology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Division of Nephrology and Hypertension, University of North Carolina Kidney Center, University of North Carolina at Chapel Hill, NC, USA.
Lancet. 2023 Sep 2;402(10404):809-824. doi: 10.1016/S0140-6736(23)01051-6.
Idiopathic nephrotic syndrome is the most common glomerular disease in children. Corticosteroids are the cornerstone of its treatment, and steroid response is the main prognostic factor. Most children respond to a cycle of oral steroids, and are defined as having steroid-sensitive nephrotic syndrome. Among the children who do not respond, defined as having steroid-resistant nephrotic syndrome, most respond to second-line immunosuppression, mainly with calcineurin inhibitors, and children in whom a response is not observed are described as multidrug resistant. The pathophysiology of nephrotic syndrome remains elusive. In cases of immune-mediated origin, dysregulation of immune cells and production of circulating factors that damage the glomerular filtration barrier have been described. Conversely, up to a third of cases of steroid-resistant nephrotic syndrome have a monogenic origin. Multidrug resistant nephrotic syndrome often leads to kidney failure and can cause relapse after kidney transplant. Although steroid-sensitive nephrotic syndrome does not affect renal function, most children with steroid-sensitive nephrotic syndrome have a relapsing course that requires repeated steroid cycles with significant side-effects. To minimise morbidity, some patients require steroid-sparing immunosuppressive agents, including levamisole, mycophenolate mofetil, calcineurin inhibitors, anti-CD20 monoclonal antibodies, and cyclophosphamide. Close monitoring and preventive measures are warranted at onset and during relapse to prevent acute complications (eg, hypovolaemia, acute kidney injury, infections, and thrombosis), whereas long-term management requires minimising treatment-related side-effects. A subset of patients have active disease into adulthood.
特发性肾病综合征是儿童中最常见的肾小球疾病。皮质类固醇是其治疗的基石,而类固醇反应是主要的预后因素。大多数儿童对一个周期的口服类固醇有反应,被定义为具有类固醇敏感性肾病综合征。在没有反应的儿童中,被定义为具有类固醇抵抗性肾病综合征,大多数对二线免疫抑制治疗有反应,主要是使用钙调神经磷酸酶抑制剂,而对治疗没有反应的儿童被描述为多药耐药。肾病综合征的病理生理学仍然难以捉摸。在免疫介导的情况下,已经描述了免疫细胞的失调和产生循环因子,这些因子会损害肾小球滤过屏障。相反,多达三分之一的类固醇抵抗性肾病综合征具有单基因起源。多药耐药性肾病综合征常导致肾衰竭,并可导致肾移植后复发。尽管类固醇敏感性肾病综合征不影响肾功能,但大多数类固醇敏感性肾病综合征患儿有复发性病程,需要多次使用类固醇循环治疗,且副作用明显。为了尽量减少发病率,一些患者需要类固醇保存免疫抑制剂,包括左旋咪唑、霉酚酸酯、钙调神经磷酸酶抑制剂、抗 CD20 单克隆抗体和环磷酰胺。在发病和复发时需要密切监测和预防措施,以预防急性并发症(如血容量不足、急性肾损伤、感染和血栓形成),而长期管理需要尽量减少治疗相关的副作用。一部分患者在成年后仍有活动性疾病。